SmartPA Criteria Proposal

Drug/Drug Class:	Continuous Glucose Monitors (CGMs) Clinical Edit
First Implementation Date:	April 2, 2020
Revised Date:	June 15, 2023
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	☐Existing Criteria ☒Revision of Existing Criteria ☐New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of Continuous Glucose Monitors (CGMs)

Why Issue Selected: Continuous Glucose Monitors (CGMs) are devices which can monitor a patient's glucose levels in the interstitial fluid consistently (every 5 to 15 minutes) versus traditional self-monitoring of blood glucose which is patient initiated at prescribed intervals throughout the day. CGMs allow patients and providers to respond to changing glucose readings more quickly, provide alarms to indicate when glucose levels are outside of threshold levels, and can indicate trends in glucose levels over time. CGMs may also lead to modest improvements in A1C and intensification of glucose control without increasing the risk of hypoglycemia. The 2021 American Association of Clinical Endocrinology Clinical Practice Guideline recommends CGMs for all persons with diabetes treated with intensive insulin therapy, defined as 3 or more injections of insulin per day or the use of an insulin pump, as well as for all individuals with problematic hypoglycemia. MO HealthNet will impose clinical criteria to ensure appropriate utilization of Dexcom G6 and G7 products for select participants who desire to utilize CGMs.

Program-Specific Information:

Date Range FFS 10-01-2021 to 9-30-2022			
Drug	**Claims**	**Spend**	**Avg Spend per Claim**
DEXCOM G6 RECEIVER	2,697	$985,216.61	$365.30
DEXCOM G6 TRANSMITTER	9,905	$2,370,378.18	$239.31
DEXCOM G6 SENSOR	26,165	$8,889,317.30	$339.74
DEXCOM G7 RECEIVER	0	-	-
DEXCOM G7 SENSOR	0	-	-

Type of Criteria:
☐ **Increased risk of ADE** ☐ **Preferred Drug List**
☒ **Appropriate Indications** ☒ **Clinical Edit**

Data Sources:
☐ **Only Administrative Databases** ☒ **Databases + Prescriber-Supplied**

Setting & Population

- Drug class for review: Continuous Glucose Monitors (CGMs)
- Age range: All appropriate MO HealthNet participants

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.
Other company trademarks are also acknowledged.

Approval Criteria

- Participant requires **any** insulin administration ~~**multiple times per day or use of an insulin pump**~~ **OR**
- Participant has a history of hypoglycemia, a hypoglycemic event, or a comorbidity that poses an unusual challenge with concomitant hypoglycemia or hyperglycemia (e.g., uncontrolled epilepsy) **OR**
- Participant is visually impaired

Denial Criteria

- Therapy will be denied if no approval criteria are met
- Claim exceeds quantity limitations:
  - 1 receiver every 310 days
  - 1 transmitter every 76 days
  - 3 sensors every 25 days

Required Documentation

Laboratory Results:		Progress Notes:	X
MedWatch Form:		Other:	X

Disposition of Edit

Denial: Exception code “0682” (Clinical Edit)
Rule Type: N

Default Approval Period

1 year

References

- DEXCOM. Continuous Glucose Monitoring for Healthcare Professionals | Dexcom Provider. Accessed March 1, 2023.
- Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. Endocr Pract. 2021;27(6):505-537. American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus (endocrinepractice.org) doi:10.1016/j.eprac.2021.04.008

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.
Other company trademarks are also acknowledged.